Tags

Type your tag names separated by a space and hit enter

Metabolic studies of delta-9-tetrahydrocannabinol in cancer patients.
Cancer Treat Rep. 1984 Dec; 68(12):1427-31.CT

Abstract

The metabolism of oral delta-9-tetrahydrocannabinol (THC) was studied in nine patients with gastrointestinal neoplasms receiving chemotherapy regimens containing 5-FU and semustine. Plasma levels of THC and its metabolites 11-OH-delta-9-THC (11-OH-THC) and 11-nor-9-carboxy-delta-9-THC (C-THC) were measured. Plasma levels of THC and its metabolites were quite variable among the patients studied. Plasma levels of THC and 11-OH-THC tended to peak at the same time; the C-THC levels peaked later and lasted much longer than the others. Mean half-lives of THC, 11-OH-THC, and C-THC were estimated to be 1.5, 2.1, and 4.4 hours, respectively. Multiple doses of THC did not produce a significant additive effect on the plasma concentrations of the biologically active metabolites THC and 11-OH-THC. No correlation between antiemetic effect or cannabinoid toxicity and plasma levels of the three metabolites could be made in this small number of patients.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

6095996

Citation

Frytak, S, et al. "Metabolic Studies of Delta-9-tetrahydrocannabinol in Cancer Patients." Cancer Treatment Reports, vol. 68, no. 12, 1984, pp. 1427-31.
Frytak S, Moertel CG, Rubin J. Metabolic studies of delta-9-tetrahydrocannabinol in cancer patients. Cancer Treat Rep. 1984;68(12):1427-31.
Frytak, S., Moertel, C. G., & Rubin, J. (1984). Metabolic studies of delta-9-tetrahydrocannabinol in cancer patients. Cancer Treatment Reports, 68(12), 1427-31.
Frytak S, Moertel CG, Rubin J. Metabolic Studies of Delta-9-tetrahydrocannabinol in Cancer Patients. Cancer Treat Rep. 1984;68(12):1427-31. PubMed PMID: 6095996.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Metabolic studies of delta-9-tetrahydrocannabinol in cancer patients. AU - Frytak,S, AU - Moertel,C G, AU - Rubin,J, PY - 1984/12/1/pubmed PY - 1984/12/1/medline PY - 1984/12/1/entrez SP - 1427 EP - 31 JF - Cancer treatment reports JO - Cancer Treat Rep VL - 68 IS - 12 N2 - The metabolism of oral delta-9-tetrahydrocannabinol (THC) was studied in nine patients with gastrointestinal neoplasms receiving chemotherapy regimens containing 5-FU and semustine. Plasma levels of THC and its metabolites 11-OH-delta-9-THC (11-OH-THC) and 11-nor-9-carboxy-delta-9-THC (C-THC) were measured. Plasma levels of THC and its metabolites were quite variable among the patients studied. Plasma levels of THC and 11-OH-THC tended to peak at the same time; the C-THC levels peaked later and lasted much longer than the others. Mean half-lives of THC, 11-OH-THC, and C-THC were estimated to be 1.5, 2.1, and 4.4 hours, respectively. Multiple doses of THC did not produce a significant additive effect on the plasma concentrations of the biologically active metabolites THC and 11-OH-THC. No correlation between antiemetic effect or cannabinoid toxicity and plasma levels of the three metabolites could be made in this small number of patients. SN - 0361-5960 UR - https://www.unboundmedicine.com/medline/citation/6095996/Metabolic_studies_of_delta_9_tetrahydrocannabinol_in_cancer_patients_ L2 - https://www.lens.org/lens/search/patent/list?q=citation_id:6095996 DB - PRIME DP - Unbound Medicine ER -